BRIEF published on 12/11/2025 at 07:05, 2 months 3 days ago BioVersys lance un essai de phase 3 pour le BV100 et fait le point sur ses progrès commerciaux. Introduction En Bourse BioVersys Résistance Aux Médicaments BV100 Phase 3 Recherche Antibactérienne
BRIEF published on 12/11/2025 at 07:05, 2 months 3 days ago BioVersys Initiates Phase 3 Trial for BV100 and Updates Business Progress IPO Drug Resistance BioVersys BV100 Phase 3 Antibacterial Research
PRESS RELEASE published on 12/11/2025 at 07:00, 2 months 3 days ago BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update BioVersys AG initiates BV100 Phase 3 study for ventilator-associated bacterial pneumonia, achieving significant milestones in 2025 and upcoming key events in 2026 Clinical Trials Biopharmaceutical BioVersys AG BV100 Phase 3 Ventilator Associated Bacterial Pneumonia
BRIEF published on 11/10/2025 at 07:05, 3 months 4 days ago L'étude de phase 2B BV100 de BioVersys est prévue pour l'Asie Essai De Phase 2b Résistance Aux Médicaments BioVersys BV100 Financement Wellcome Réseau ADVANCE-ID
BRIEF published on 11/10/2025 at 07:05, 3 months 4 days ago BioVersys' BV100 Phase 2B Study Set for Asia Phase 2B Trial Drug Resistance BioVersys BV100 Wellcome Funding ADVANCE-ID Network
PRESS RELEASE published on 11/10/2025 at 07:00, 3 months 4 days ago BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network. BioVersys AG leads Phase 2 trial for innovative antibacterial product BV100 Phase 2b Clinical Trial BV100 BioVersys Wellcome Funded Trial Network
BRIEF published on 11/06/2025 at 07:05, 3 months 8 days ago BioVersys Advances BV100 Clinical Trials in China Clinical Trials BV100 BioVersys MDR Bacteria Acinetobacter
BRIEF published on 11/06/2025 at 07:05, 3 months 8 days ago BioVersys fait progresser les essais cliniques du BV100 en Chine Essais Cliniques BV100 BioVersys Bactéries Multirésistantes Acinetobacter
PRESS RELEASE published on 11/06/2025 at 07:00, 3 months 8 days ago Bioversys ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF BV100 in CHInA BioVersys announces the dosing of the first subject in a Phase 1 clinical trial with BV100 in China. BV100 targets MDR hospital infections caused by Acinetobacter baumannii Phase 1 Clinical Trial BV100 BioVersys MDR Bacteria Acinetobacter Baumannii
BRIEF published on 11/05/2025 at 07:05, 3 months 9 days ago BioVersys to Present at Stifel 2025 Annual Healthcare Conference New York City Healthcare Conference Clinical Developments BioVersys Multi-drug Resistant Bacteria
Published on 02/14/2026 at 01:00, 11 hours 38 minutes ago Orogen Royalties Announces Annual Equity Compensation Grant
Published on 02/13/2026 at 22:15, 14 hours 23 minutes ago Storm Completes Sale of Miminiska Project for $5.8M and Outlines Plans for 2026
Published on 02/13/2026 at 17:45, 18 hours 53 minutes ago Eldorado Gold Closes $2.4 Million Strategic Investment in Gemdale Gold
Published on 02/13/2026 at 14:35, 22 hours 3 minutes ago Datametrex Received $500,000 Purchase Order For Data Centre Solutions
Published on 02/14/2026 at 06:05, 6 hours 33 minutes ago The 139th Canton Fair Promotion Conferences to Be Held in Germany and Morocco, Highlighting Targeted Industry Opportunities
Published on 02/13/2026 at 19:20, 17 hours 18 minutes ago Retail offering successfully completed and update on Euronext Growth Oslo listing
Published on 02/13/2026 at 19:01, 17 hours 37 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/13/2026 at 18:20, 18 hours 18 minutes ago GLOBAL TECHNOLOGY LEADERS LAUNCH TRUSTED TECH ALLIANCE
Published on 02/13/2026 at 18:07, 18 hours 30 minutes ago EQS-Adhoc: Delticom AG: Based on preliminary, unaudited figures for the FY 2025, full-year revenues are below the forecast, while operating EBITDA is expected to be at the upper end of the forecasted range
Published on 02/13/2026 at 18:05, 18 hours 33 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/01/2026
Published on 02/13/2026 at 18:05, 18 hours 33 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/01/2026
Published on 02/13/2026 at 17:50, 18 hours 48 minutes ago Number of shares and voting rights - January 2026 (In French only)
Published on 02/13/2026 at 17:50, 18 hours 48 minutes ago Nombre total d'actions et droits de vote - janvier 2026
